Squamous Cell Carcinoma Arising from Mature Cystic Teratoma Treated by Immunotherapy: A Case Report

被引：0
作者：
Aref Zribi [1 ]
Reem al Mazroui [2 ]
Asma Naz Nadaf [3 ]
Ikram A. Burney [1 ]
机构：
[1] Women Health Program, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Muscat
[2] Department of Radiology, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Muscat
[3] Department of Pathology, Sultan Qaboos Comprehensive Cancer Care and Research Centre, University Medical City, Muscat
来源：
Indian Journal of Gynecologic Oncology | 2025年 / 23卷 / 2期
关键词：
Immune checkpoint inhibitor; Neoplastic transformation; Ovary; Squamous cell carcinoma; Teratoma;
D O I：
10.1007/s40944-025-01002-3
中图分类号：
学科分类号：
摘要：
Background: Squamous cell carcinoma (SCC) of the ovary is a rare disease. The disease is resistant to chemotherapy and has a poor prognosis. Optimal first-line treatment is unclear, to our knowledge there are only 05 cases report of SCC arising from mature cystic teratoma (SCC-MCT) treated with immunotherapy. Case presentation: We report the case of recurrent metastatic SCC-MCT, in 32-year-old female Arab patient who was treated with Nivolumab after immunohistochemistry showed a high combined positive score (CPS) of 45%. The disease progressed after an initial partial response and the patient succumbed to her disease. Conclusion: The prognosis of SCC-MCT remains grim. Given the success of immunotherapy in multiple solid tumors, next generation sequencing can help guide selection of those patients who may most benefit from immune checkpoint inhibitors. © The Author(s) under exclusive licence to Association of Gynecologic Oncologists of India 2025.
引用
收藏
相关论文
共 27 条
  • [1] Li C., Zhang Q., Zhang S., Et al., Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review, BMC Cancer, 19, 1, (2019)
  • [2] Hackethal A., Brueggmann D., Bohlmann M.K., Franke F.E., Tinneberg H.R., Munstedt K., Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data, Lancet Oncol, 12, 9, pp. 1173-1180, (2008)
  • [3] Li H., van der Merwe P.A., Sivakumar S., Biomarkers of response to PD-1 pathway blockade, Br J Cancer, 126, pp. 1663-1675, (2022)
  • [4] Chen R.J., Chen K.Y., Chang T.C., Et al., Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary, J Formos Med Assoc, 107, 11, pp. 857-868, (2008)
  • [5] Yoshimura K., Yamanoi K., Kanai M., Et al., Nivolumab for malignant transformation of ovarian mature cystic teratoma, Gynecol Oncol Rep, 10, 44, (2022)
  • [6] Zhang C., Ma T., Poorer prognosis of ovarian squamous cell carcinoma than serous carcinoma: a propensity score matching analysis based on the SEER database, J Ovarian Res, 13, 1, (2020)
  • [7] Park J.W., Bae J.W., Pure primary ovarian squamous cell carcinoma: a case report and review of the literature, Oncol Lett, 9, 1, pp. 321-323, (2015)
  • [8] Koufopoulos N., Nasi D., Goudeli C., Et al., Primary squamous cell carcinoma of the ovary, Review of the literature J Buon, 24, 5, pp. 1776-1784, (2019)
  • [9] Glasspool R.M., Gonzalez M.A., Millan D., Et al., Gynecologic cancer intergroup (GCIG) consensus review for squamous cell carcinoma of the ovary, Int J Gynecol Cancer, 24, 9 Suppl 3, pp. S26-S29, (2014)
  • [10] Xu Y., Li L., Primary squamous cell carcinoma arising from endometriosis of the ovary: a case report and literature review, Curr Probl Cancer, 42, 3, pp. 329-336, (2018)
123